Lee Flowers Buys 7,736 Shares of HCW Biologics (NASDAQ:HCWB) Stock

HCW Biologics Inc. (NASDAQ:HCWB) SVP Lee Flowers acquired 7,736 shares of the firm’s stock in a transaction on Wednesday, July 29th. The stock was purchased at an average cost of $2.58 per share, for a total transaction of $19,958.88. Following the completion of the acquisition, the senior vice president owned 8,691 shares in the company, valued at approximately $22,422.78. This represents a 810.05% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

HCW Biologics Stock Performance

Shares of HCW Biologics stock opened at $3.20 on Friday. The firm has a 50-day moving average of $6.50 and a 200-day moving average of $5.20. HCW Biologics Inc. has a 52-week low of $1.50 and a 52-week high of $44.10. The stock has a market cap of $5.12 million, a PE ratio of -0.06 and a beta of 2.29.

HCW Biologics (NASDAQ:HCWB) last posted its quarterly earnings data on Thursday, May 14th. The company reported $0.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.64) by $3.01. The firm had revenue of $6.54 million during the quarter, compared to the consensus estimate of $6.54 million. HCW Biologics had a negative net margin of 34.73% and a negative return on equity of 486.87%.

Hedge Funds Weigh In On HCW Biologics

An institutional investor recently bought a new position in HCW Biologics stock. Armistice Capital LLC bought a new stake in HCW Biologics Inc. (NASDAQ:HCWB) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 300,180 shares of the company’s stock, valued at approximately $291,000. Armistice Capital LLC owned approximately 9.15% of HCW Biologics at the end of the most recent reporting period. 2.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of HCW Biologics in a research note on Friday, July 17th. Maxim Group boosted their target price on shares of HCW Biologics from $12.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, May 28th. Finally, Wall Street Zen raised shares of HCW Biologics to a “hold” rating in a report on Saturday, May 23rd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $30.00.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.